The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

By afschroeder • August 1, 2025

Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025 Jul 25:S0140-6736(25)01042-6. doi: 10.1016/S0140-6736(25)01042-6. Epub ahead of print. PMID: 40744051.

Tags: Hematology/Oncology, Publications

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]

Long-Term Survival After Percutaneous Image-Guided Thermal Ablation of Oligometastatic Renal Cell Carcinoma

Kim DH, Keshavarz P, Tibbe TD, Suh RD, Abtin F, Genshaft SJ, Drakaki A, Shuch BM, Pantuck AJ, Lu DS, Raman SS. Long-Term Survival After[...]

Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma

Mar N, Cabral MY, Go J, Kaakour D, Dwabe S, Seyedin SN, Drakaki A. Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without[...]